Journal
EXPERT REVIEW OF OPHTHALMOLOGY
Volume 2, Issue 3, Pages 363-368Publisher
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1586/17469899.2.3.363
Keywords
benzalkonium chloride; glaucoma; medications; sofZia (TM); travoprost Z; travoprost ophthalmic solution 0.004%
Categories
Funding
- Alcon
Ask authors/readers for more resources
Travoprost Z (Travatan((R)) Z) ophthalmic solution has recently been approved for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. This new ophthalmic solution contains travoprost 0.004% as the active ingredient with sofZia (TM) as the preservative system consisting of zinc, borate, propylene glycol and sorbitol, and designed to be dissipated by the ocular tear film. Available clinical data have documented equal IOP-lowering safety and efficacy of travoprost Z when compared with travoprost preserved with benzalkonium chloride. This article discusses the current evidence on the clinical efficacy and safety of this recently released solution and expands on the potential benefits and future goals of newer preservative systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available